Dificlir

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
22-12-2022
Produktens egenskaper Produktens egenskaper (SPC)
22-12-2022

Aktiva substanser:

fidaxomicin

Tillgänglig från:

Tillotts Pharma GmbH

ATC-kod:

A07AA12

INN (International namn):

fidaxomicin

Terapeutisk grupp:

Antidiarrheals, intestinal antiinflammatory / antiinfective agents

Terapiområde:

Clostridium Infections

Terapeutiska indikationer:

Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Produktsammanfattning:

Revision: 17

Bemyndigande status:

Authorised

Tillstånd datum:

2011-12-05

Bipacksedel

                                32
B. PACKAGE LEAFLET
33
PACKAGE LEAFLET: INFORMATION FOR THE USER
DIFICLIR 200 MG FILM-COATED TABLETS
fidaxomicin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor or pharmacist.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
−
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What DIFICLIR is and what it is used for
2.
What you need to know before you take DIFICLIR
3.
How to take DIFICLIR
4.
Possible side effects
5.
How to store DIFICLIR
6.
Contents of the pack and other information
1.
WHAT DIFICLIR IS AND WHAT IT IS USED FOR
DIFICLIR is an antibiotic which contains the active substance
fidaxomicin.
DIFICLIR film-coated tablets are used in adults, adolescents and
children with a body weight of at
least 12.5 kg to treat infections of the lining of the colon (large
intestine) with certain bacteria called
_Clostridioides difficile_
. This serious illness can result in painful, severe diarrhoea.
DIFICLIR works by
killing the bacteria that cause the infection and helps to reduce the
associated diarrhoea.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DIFICLIR
DO NOT TAKE DIFICLIR
−
If you are allergic to fidaxomicin or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking DIFICLIR.
If you feel that you might have a severe allergic reaction such as
trouble breathing (dyspnea), swelling
of the face or throat (angioedema), severe rash, severe itching
(pruritus) or severe hives (urticaria),
stop taking DIFICLIR and seek medical advice urgently from your
doctor, pharmacist or at your local
hospital emergency department (see section
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
DIFICLIR 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 200 mg of fidaxomicin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Capsule shaped tablets of 14 mm, white to off-white in colour,
debossed with “FDX” on one side and
“200” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
DIFICLIR film-coated tablets is indicated for the treatment of
_Clostridioides difficile_
infections (CDI)
also known as
_C. difficile_
-associated diarrhoea (CDAD) in adult and paediatric patients with a
body
weight of at least 12.5 kg (see section 4.2 and 5.1).
Consideration should be given to official guidelines on the
appropriate use of antibacterial agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults _
Standard dosing
_ _
The recommended dose is 200 mg (one tablet) administered twice daily
(once every 12 hours) for
10 days (see section 5.1).
DIFICLIR 40 mg/ml granules for oral suspension may be used in adult
patients with difficulties in
swallowing tablets.
Extended-pulsed dosing
Fidaxomicin 200 mg tablets administered twice daily for days 1-5 (no
intake of a tablet on day 6) then
once daily on alternate days for days 7-25 (see section 5.1).
If a dose has been forgotten, the missed dose should be taken as soon
as possible or, if it's nearly time
for the next dose, the tablet should be skipped altogether.
Special populations
_Elderly population _
No dose adjustment is considered necessary (see section 5.2).
_Renal impairment _
No dose adjustment is considered necessary. Due to the limited
clinical data in this population,
fidaxomicin should be used with caution in patients with severe renal
impairment (see sections 4.4 and
3
5.2).
_Hepatic impairment _
No dose adjustment is considered necessary. Due to the limited
clinical data in this population,
fidaxomicin should be used with caution in patients with moderat
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 22-12-2022
Produktens egenskaper Produktens egenskaper bulgariska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 11-03-2020
Bipacksedel Bipacksedel spanska 22-12-2022
Produktens egenskaper Produktens egenskaper spanska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 11-03-2020
Bipacksedel Bipacksedel tjeckiska 22-12-2022
Produktens egenskaper Produktens egenskaper tjeckiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 11-03-2020
Bipacksedel Bipacksedel danska 22-12-2022
Produktens egenskaper Produktens egenskaper danska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 11-03-2020
Bipacksedel Bipacksedel tyska 22-12-2022
Produktens egenskaper Produktens egenskaper tyska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 11-03-2020
Bipacksedel Bipacksedel estniska 22-12-2022
Produktens egenskaper Produktens egenskaper estniska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 11-03-2020
Bipacksedel Bipacksedel grekiska 22-12-2022
Produktens egenskaper Produktens egenskaper grekiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 11-03-2020
Bipacksedel Bipacksedel franska 22-12-2022
Produktens egenskaper Produktens egenskaper franska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 11-03-2020
Bipacksedel Bipacksedel italienska 22-12-2022
Produktens egenskaper Produktens egenskaper italienska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 11-03-2020
Bipacksedel Bipacksedel lettiska 22-12-2022
Produktens egenskaper Produktens egenskaper lettiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 11-03-2020
Bipacksedel Bipacksedel litauiska 22-12-2022
Produktens egenskaper Produktens egenskaper litauiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 11-03-2020
Bipacksedel Bipacksedel ungerska 22-12-2022
Produktens egenskaper Produktens egenskaper ungerska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 11-03-2020
Bipacksedel Bipacksedel maltesiska 22-12-2022
Produktens egenskaper Produktens egenskaper maltesiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 11-03-2020
Bipacksedel Bipacksedel nederländska 22-12-2022
Produktens egenskaper Produktens egenskaper nederländska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 11-03-2020
Bipacksedel Bipacksedel polska 22-12-2022
Produktens egenskaper Produktens egenskaper polska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 11-03-2020
Bipacksedel Bipacksedel portugisiska 22-12-2022
Produktens egenskaper Produktens egenskaper portugisiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 11-03-2020
Bipacksedel Bipacksedel rumänska 22-12-2022
Produktens egenskaper Produktens egenskaper rumänska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 11-03-2020
Bipacksedel Bipacksedel slovakiska 22-12-2022
Produktens egenskaper Produktens egenskaper slovakiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 11-03-2020
Bipacksedel Bipacksedel slovenska 22-12-2022
Produktens egenskaper Produktens egenskaper slovenska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 11-03-2020
Bipacksedel Bipacksedel finska 22-12-2022
Produktens egenskaper Produktens egenskaper finska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 11-03-2020
Bipacksedel Bipacksedel svenska 22-12-2022
Produktens egenskaper Produktens egenskaper svenska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 11-03-2020
Bipacksedel Bipacksedel norska 22-12-2022
Produktens egenskaper Produktens egenskaper norska 22-12-2022
Bipacksedel Bipacksedel isländska 22-12-2022
Produktens egenskaper Produktens egenskaper isländska 22-12-2022
Bipacksedel Bipacksedel kroatiska 22-12-2022
Produktens egenskaper Produktens egenskaper kroatiska 22-12-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 11-03-2020

Sök varningar relaterade till denna produkt

Visa dokumenthistorik